Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis
- 1.3k Downloads
Background Biological drugs for moderate-to-severe ulcerative colitis have changed the therapeutic perspective, while small-molecule inhibitors and new promising drugs suggest new options. Aim Assess comparative efficacy and safety of biological and new small oral drugs: commercialized and under-investigation ones for patients naïve to biological drugs. Methods A systematic review was conducted to identify the randomized clinical trials phase 2 or 3, in adults with moderate-to-severe ulcerative colitis treated with biological drugs (infliximab, adalimumab, golimumab, vedolizumab and etrolizumab) or new oral small molecules (tofacitinib and ozanimod) as first line. A Bayesian network metaanalysis was performed to inform comparative efficacy and safety of different treatments. Efficacy outcomes were clinical remission, clinical response and mucosal healing for induction therapy and clinical remission, mucosal healing and sustained clinical remission for maintenance therapy. Safety was assessed with serious adverse events and rates of infections. Results 14 references were included for network meta-analysis. For induction therapy, infliximab was the best drug for induction of clinical response and remission, while ozanimod showed to be the best for induction of mucosal healing. Tofacitinib had the highest rate of maintaining clinical remission. All treatments were similar for serious adverse events, and vedolizumab and tofacitinib had the highest rates of infections. Conclusion This network meta-analysis suggests infliximab may be the best therapeutic option for moderate-to-severe ulcerative colitis. Vedolizumab seems to have better outcomes in maintenance than in induction therapy and it appears superior to golimumab and adalimumab. Tofacitinib, ozanimod and etrolizumab show encouraging results.
KeywordsBiological drugs Network meta-analysis New small oral molecules Ulcerative colitis
This work was done for a doctoral thesis, and the authors constitute an independent group.
This study was done without any financial support.
Conflicts of interest
All authors declare that they have no conflicts of interest.
- 9.Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value Heal. 2015;17:157–73.CrossRefGoogle Scholar
- 13.Van Valkenhoef G, Kuiper J. gemtc: network meta-analysis using Bayesian methods. 2015; R package version 0.8-2; 2016.Google Scholar
- 14.Plummer M. JAGS: Just another Gibbs sampler (Version 3.4.0)[Software]; 2013. http://mcmc-jags.sourceforge.net/.
- 16.Brooks SPB, Gelman AG. General methods for monitoring convergence of iterative simulations. J Comput Gr Stat. 1998;7:434–55.Google Scholar
- 32.Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013;146(96–109):e1.Google Scholar
- 33.Hibi T, Imai Y, Senoo A, Ohta K, Ukyo Y. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study (PURSUIT-J study). J Gastroenterol. 2017;52:1101–11.CrossRefGoogle Scholar
- 38.Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.CrossRefGoogle Scholar
- 44.Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2017;00:1–12. https://doi.org/10.1111/apt.14449.CrossRefGoogle Scholar
- 45.Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15(229–239):e5.Google Scholar
- 46.European Medicines Agency. Infliximab product information. 2018. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR__Product_Information/human/000240/WC500050888.pdf.
- 47.European Medicines Agency. Golimumab product information. 2018. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR__Product_Information/human/000992/WC500052368.pdf.
- 48.European Medicines Agency. Humira product information. 2018. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR__Product_Information/human/000481/WC500050870.pdf.
- 49.European Medicines Agency: Vedolizumab product information. 2018. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR__Product_Information/human/002782/WC500168528.pdf.